Videos

Ruben Mesa, MD, discusses the results from a reanalysis of the phase II JAKARTA-2 study in patients with myelofibrosis (MF) who received a previous treatment of ruxolitinib (Jakafi) and failed treatment.

David Spigel, MD, chief scientific officer, Sarah Cannon Research Institute, director of the Lung cancer Research Program, and member of the Association of Community Cancer Centers explains to <em>Targeted Oncology, </em>the ways in which ACCC is improving the care landscape and outcomes for patients with advanced non&ndash;small cell lung cancer.

The Rapid Integration Program, a training initiative for new physician&rsquo;s assistants and nurse practitioners working in the field of oncology, is a Florida Society of Community Oncology (FLASCO) initiative that came from an ASCO meeting. Winston Tan, MD, of the Head and Neck Cancer Center at the Mayo Clinic in Jacksonville, Florida, speaking during the 2019 ASCO Annual Meeting, was in attendance at the 2016 ASCO Annual Meeting when the idea for a training program was first introduced.<br /> &nbsp;

Hodgkin Lymphoma

Ezzat Elhassadi, MD, a consultant hematologist at the University Hospital Waterford in Ireland, discusses the therapeutic approach for different subtypes of mantle cell lymphoma. MCL is a spectrum of diseases that should be treated differently, he says.

Susan Friedman, executive director and founder, FORCE, a non-profit organization supporting education, advocacy, and research around breast and ovarian cancer, explains the relevance of PARP inhibitors and the recent developments in oncology research that may improve cancer treatment for patients with genetic mutations.